The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety Authority was requested to evaluate the genotoxic potential of flavouring substances from subgroup 1.
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION
The use of flavouring is regulated under Regulation (EC) No 1334/2008 4 of the European Parliament and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring properties for use in and on foods. On the basis of article 9(a) of this Regulation an evaluation and approval are required for flavouring substances.
The Union List of flavourings and source materials was established by Commission Implementing Regulation (EC) No 872/2012 5 . The list contains flavouring substances for which the scientific evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000 6 .
EFSA has evaluated 17 flavouring substances, which correspond to subgroup 1.1.4 of FGE.19, in its evaluation of the flavouring group 203 (FGE.203). The opinion was adopted on 27 November 2008.
EFSA concluded that there is a safety concern for hexa-2(trans),4(trans)-dienal .057] since a non-threshold mechanism cannot be excluded. Therefore, the substances of this FGE cannot be evaluated through the Procedure and requested data which clarify whether the carcinogenic effects were based on a thresholded mechanism.
Information on two representative materials hexa-2(trans),4(trans)-dienal .057] and deca-2(trans),4(trans)-dienal ] has now been submitted by the European Flavour Association. This information is intended to cover the re-evaluation of the above mentioned substances and of the following 18 substances from FGE.19 subgroup 1. The Commission asks EFSA to evaluate this new information and depending on the outcome proceed to the full evaluation of the flavouring substances.
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION
The European Commission requests the European Food Safety Authority to carry out a safety assessment on the following 20 flavouring substances: deca-2,4-dien-1-ol 4, 4, 2, 
HISTORY OF FGE.19
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl substances via hydrolysis and/or oxidation (EFSA, 2008a) .
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 2008a) . The Panel noted that there were limited genotoxicity data on these flavouring substances but that positive genotoxicity studies were identified for some substances in the group.
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity (EFSA, 2008a) . In an attempt to decide which of the substances could go through the Procedure, a (quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE Models and ISS-Local Models, (Gry et al., 2007) ).
The Panel noted that for most of these models internal and external validation has been performed, but considered that the outcome of these validations was not always extensive enough to appreciate the validity of the predictions of these models for these alpha, beta-unsaturated carbonyls. Therefore, the Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided not to take substances through the procedure based on negative (Q)SAR predictions only.
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 subgroups (1.1.1, 1.2.1, 1.2.2, 1.2. 3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5. 3) (EFSA, 2008a) could not be evaluated through the Procedure due to concern with respect to genotoxicity. Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established: FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225. For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, that a further scrutiny of the data should take place before requesting additional data from the Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 213, 214, 216, 217, 218 and 220 . For the substances in FGE.202, 214 and 218 it was concluded that a genotoxic potential could be ruled out and accordingly these substances will be evaluated using the Procedure. For all or some of the substances in the remaining FGEs, FGE.201. 203, 210, 212, 213, 216, 217 and 220 the genotoxic potential could not be ruled out.
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the different subgroups for which additional data are requested, EFSA worked out a list of representative substances for each subgroup (EFSA, 2008c) . Likewise an EFSA genotoxicity expert group has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008b) .
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list of representative substances and test strategy for each subgroup.
The Flavouring industry has now submitted additional data and the present FGE concerns the evaluation of these data requested on genotoxicity.
ASSESSMENT

1.
History of the Evaluation of the Substances in Subgroup 1.1.4
In November 2008, the Panel concluded based on the in vitro and in vivo genotoxicity data and carcinogenicity data available at that time as well as on the outcome of the (Q)SAR predictions that there is a safety concern for hexa-2(trans),4(trans)-dienal [FL-no: 05.057] since a non-threshold mechanism cannot be excluded. The Panel requested data which clarify whether the carcinogenic effects were based on a threshold mechanism. This conclusion also applies to the other substances of this FGE.203 (EFSA, 2009 Table 3 ).
A summary of their current evaluation status by JECFA is given in The Panel has also taken into consideration the outcome of the predictions from five selected (Q)SAR models (Benigni and Netzeva, 2007a; Gry et al., 2007; Nikolov et al., 2007) Table 10 .
Section 3 reports the same information that was presented in FGE.203. Section 4 describes additional data submitted by the Industry in response to the data requested in FGE.203.
Toxicity
(Q)SAR Predictions
In 
Carcinogenicity Studies
Groups of 50 male and 50 female F344/N rats were administered 2,4-hexadienal (89 % trans,transisomer, 11 % cis,trans-isomer) in corn oil by gavage at dose levels of 0 (controls), 22.5, 45 or 90 mg/kg body weight (bw) per day, five times per week for up to 105 weeks. The survival of the dosed animals was not affected by the treatment. The mean body weights of the high dose males were generally lower than that of the controls. The incidences of squamous cell papillomas of the forestomach occurred with a statistically significant positive trend in male and female rats (males: 0/50; 3/50; 10/50; 29/50; females: 0/50; 1/50; 5/50; 17/50). Squamous cell carcinomas were found in one male at 45 mg/kg bw per day and in two males at the highest dose group (males papillomas and carcinomas: 0/50; 3/50; 11/50; 29/50). Incidence of epithelial hyperplasia were statistically significantly increased in rats at all dose levels (males: 3/50; 19/50; 42/50; 50/50; females: 2/50; 16/50; 37/50; 41/50) (NTP, 2003) .
Groups of 50 male and 50 female B6C3F1 mice were administered 2,4-hexadienal in corn oil by gavage at dose levels of 0 (controls), 30, 60, or 120 mg/kg bw/day, five times per week for 105 weeks. The survival and the mean body weights of the dosed animals were not affected by the treatment. The incidences of squamous cell papillomas of the forestomach occurred with a statistically significant positive trend in male and female mice (males: 2/50; 4/50; 5/50; 8/50; females: 2/50; 2/50; 11/50; 13/50). Squamous cell carcinomas were found in males and females at the highest dose group (males carcinomas: 0/50; 1/50; 0/50; 2/50; males papillomas and carcinomas: 2/50; 4/50; 5/50; 10/50; females carcinomas: 0/50; 0/49; 0/50; 7/50; females papillomas and carcinomas: 2/50; 2/49; 11/50; 18/50). Epithelial hyperplasia occurred in mice of either sex at the highest dose level (males: 14/50; 7/50; 9/50; 26/50; females: 4/50; 8/49; 12/50; 31/50). Two males from the highest dose group had squamous cell carcinoma of the tongue (NTP, 2003) . Although not statistically significantly increased relative to the controls, this increase exceeded historical incidences in controls.
Additional studies were performed by NTP (NTP, 2003) in order "to evaluate whether oral administration of 2,4-hexadienal to F344/N rats induces the formation of the lipid peroxidation product malondialdehyde in the forestomach and/or affects the defensive antioxidant glutathione system. Forestomach samples were collected from groups of 10 male and 10 female F344/N rats administered 0, 90, or 120 mg/kg 2,4-hexadienal in corn oil by gavage for 28 days to measure the concentrations of reduced glutathione (GSH), oxidized glutathione (GSSG), and malondialdehyde (MDA). The concentration of GSH increased significantly in males at 1 and 4 hours postdosing and in females at 4 and 24 hours postdosing. The concentration of GSSG increased significantly in males at all three timepoints and in females at 4 and 24 hours postdosing. The concentration of GSH + GSSG increased significantly in males at 4 hours postdosing and in females at 4 and 24 hours postdosing. There was a significant reduction of the GSH/GSSG ratio in males at 4 hours postdosing and no significant trend at other times. No statistically significant changes in the concentration of MDA were observed in the forestomach of male or female rats".
The hypothesis that treatment with this dienal can result in an increase in the endogenous formation of acrolein and crotonaldehyde-derived cyclic DNA adducts in the target tissues was also investigated by NTP (NTP, 2003) : "DNA adduct analysis was performed on samples of liver and forestomach tissue from male F344/N rats and forestomach tissue from B6C3F1 mice administered 0, 90 (rats only), or 120 (mice only) mg 2,4-hexadienal/kg body weight by gavage. Vehicle control male rats were treated for 118 days; all other rats and mice were treated for 90 days.
Following 90 days of administration, there was no significant difference in the concentration of DNA adducts detected in liver samples of vehicle control and 90 mg/kg male rats. In rat forestomach samples, Acr-dG 3 concentrations appeared to be greater in the treated group than in the vehicle control group, although the difference was not significant (P=0.079). While neither Cro-dG 1 nor Cro-dG 2 were detected in forestomach tissue from vehicle control rats, Cro-dG 2 was present in tissue from rats dosed with 90 mg/kg. These results suggest that treatment with 2,4-hexadienal may increase cyclic adduct formation in rat forestomach DNA via a lipid peroxidation pathway. In mouse forestomach tissue, no significant change in concentration of the Acr-dG 3 adduct was detected following 90 days of exposure to 120 mg/kg 2,4-hexadienal. Cro-dG adduct concentrations appeared to be greater in samples from the vehicle control group than in those from the 120 mg/kg group (P=0.0010 for Cro-dG 1; P=0.0011 for Cro-dG 2)".
Overall, the authors of the NTP report concluded (NTP, 2003) :
"Under the conditions of these 2-year gavage studies, there was clear evidence of carcinogenic activity of 2,4-hexadienal in male and female F344/N rats and male and female B6C3F1 mice based on increased incidences of squamous cell neoplasms of the forestomach. The occurrence of squamous cell carcinoma of the oral cavity (tongue) in male B6C3F1 mice may have been related to the administration of 2,4-hexadienal. Hyperplasia of the forestomach in male and female rats and mice was associated with administration of 2,4-hexadienal".
At its 61 st meeting the JECFA has discussed the occurrence of forestomach effects in rodents:
"The occurrence of forestomach hyperplasia and squamous cell tumours in rodents is common in bioassay studies by the National Toxicology Program in which a high concentration of an irritating material in corn oil is delivered daily by gavage into the forestomach for 2 years. High concentrations of aldehydes (e.g. malonaldehyde, furfural, benzaldehyde and trans,trans-2,4-hexadienal (National Toxicology Program, 1988 , 1990 , 1993 , 2001 and other irritating substances (e.g. dihydrocoumarin, coumarin (National Toxicology Program, 1990 , 1992 ) delivered in corn oil by gavage are consistently associated with these phenomena in the forestomach of rodents.
Trans,trans-2,4-Hexadienal produced some positive results in short-term tests for genotoxicity in vitro, but was inactive in tests in vivo. Thus, although it may be genotoxic under some conditions, this is not believed to be the basis for its effects in the rodent forestomach. There was evidence of treatment-related injury to the forestomach epithelium and this is believed to be the primary cause of the neoplastic development. In the bioassays, development of hyperplasia in mice and rats receiving test substance by gavage in corn oil, and a low incidence of adenoma observed in mice reflect the sensitivity of the forestomach to irritation. The forestomach was the only site at which an increased incidence of neoplasia was observed in treated animals.
The relevance of the development of forestomach tumours in rodents to potential carcinogenic targets in humans has been the subject of much investigation (Grice, 1988; Wester & Kroes, 1988; Clayson et al., 1990 ). An International Agency for Research on Cancer Working Group (IARC, 2003) concluded that in order to evaluate the relevance of the induction of forestomach tumours in rodents to cancer in humans, the exposure conditions used in these experiments have to be considered. The exposure conditions during oral administration are unusual (particularly if dosing is effected by gavage) in that physical effects may result in high local concentrations of test substances in the forestomach and prolonged exposure of the epithelial tissue. Agents that only produce tumours in the forestomach in rodents after prolonged treatment and via mechanisms that do not involve reaction with DNA may be of less relevance to humans, since human exposure to such agents would need to surpass timeintegrated dose thresholds in order to elicit the carcinogenic response.
Therefore, the appearance of these lesions in the 2-year bioassay in rodents given trans,trans-2,4hexadienal at a high concentration by gavage has no relevance to humans, given that the results are due to the irritating effect of high bolus doses of trans,trans-2,4-hexadienal delivered to the contact site (the forestomach) by gavage and not the effects of systemic concentrations in the whole animal." (JECFA, 2004) .
Study validation and results are presented in Table 5 .
Genotoxicity Studies
In subgroup 1. Hexa-2(trans),4(trans)-dienal [FL-no: 05.057] was found positive in three valid studies with S. typhimurium TA100 strain (Eder et al., 1992; NTP, 2003) and TA104 strain (Marnett et al., 1985) . Two valid in vivo bone marrow micronucleus assays in mice and rats which have been considered as inconclusive by NTP (NTP, 2003) were considered weakly positive by the Panel. Negative results were reported in a 14-week mouse peripheral blood micronucleus assay (NTP, 2003) , considered of limited relevance due to limitations in the experimental protocol. Of limited relevance, due to several shortcomings of the studies, are considered the positive results of a SOS chromotest in E. coli PQ37, the induction of DNA-strand breaks in mouse leukemia cells and the in vitro (nucleosides) induction of DNA adducts (Eder et al., 1993) .
Nona-2,4-dienal [FL-no: 05.071] was found negative in a valid study with S. typhimurium TA104 strain (Marnett et al., 1985) . The negative results of a SOS chromotest in E. coli PQ37, as well as the positive results in a test for DNA-strand breaks in mouse leukemia cells (Eder et al., 1993) were considered of limited relevance due to several shortcomings of these studies.
Study validation and results are presented in Tables 6 and 7 .
Conclusion on Genotoxicity and Carcinogenicity
The Panel concluded that 2,4-hexadienal [FL-no: 05.057] increased the incidence of neoplasms in the forestomach of male and female rats and mice. In addition, squamous cell carcinoma of the tongue was observed in two mice of the high dose group. Based on the data available a non-threshold genotoxic mechanism cannot be excluded. This conclusion also applies to the other substances in this FGE likewise.
Conclusions for FGE.203
Based on the available data on carcinogenicity and genotoxicity there is a safety concern for hexa-2(trans),4(trans)-dienal [FL-no: 05.057] since a non-threshold mechanism cannot be excluded. Therefore, the substances of this FGE cannot be evaluated through the Procedure. The Panel requests data which clarify whether the carcinogenic effects were based on a threshold mechanism.
Additional genotoxicity Data Submitted by Industry for Subgroup 1.1.4
In response to the EFSA request in FGE.203 for additional genotoxicity data for subgroup 1.1.4 the Flavour Industry (EFFA, 2013; IOFI, 2013) has submitted genotoxicity data on deca-2(trans),4(trans)dienal [05.140] (Table 2) . 
In Vitro Data
Bacterial reverse mutation assay 2,4-Decadienal was tested independently in two laboratories in S. typhimurium TA97, TA98, TA100, TA102, TA104 and TA1535 in the absence and presence of rat or hamster S9-mix, using the preincubation method. Concentrations from 0.3 to 666 μg/plate in strains TA97 and TA1535 and from 0.3 to 1000 μg/plate in TA 98 and TA 100 were tested in the first study and from 0.1 to 100 μg/plate in strains TA97, TA98, TA100, TA102, TA104, TA1535 were evaluated in the second study. The test (NTP, 2011) was performed according the OECD Guideline 471 (OECD, 1997a), following the GLP principles. In the absence of S9-mix, evidence of toxicity above 10 μg/plate and cell killing at 33 μg/plate or above was observed in all tester strains. In the presence of S9-mix signs of toxicity were observed starting from 1000 in strain TA98 (with 30 % hamster S9-mix) and from 333 or 666 μg/plate in the other tester strains. The vehicle and positive control substances produced appropriate responses. No evidence of mutagenicity was observed in any of the tester strains.
Study validation and results are presented in Table 8 .
In Vivo Data
Micronucleus assay 2,4-Decadienal was evaluated in a micronucleus assay in bone marrow PCEs for its ability to induce chromosomal damage in rats. 2,4-Decadienal dissolved in corn oil as a carrier was administered by a single intraperitoneal injection to F344/N rats (5 males/dose) at doses of 100, 200, 400 and 600 mg/kg bw. Cyclophosphamide (25 mg/kg bw) was given as the positive control. Rats from all dose groups were sampled 24 hours after dosing. At least 1000 PCEs were scored for each animal for micronuclei (MN). No cytotoxic effects were observed at any dose, as determined by a reduction in the number of PCEs versus vehicle controls. Statistically significant increase in micronuclei frequency was observed in the groups dosed with 100 to 400 mg 2,4-decadienal/kg bw (up to 6-fold compared to control) but not for the highest dose 600 mg/kg bw, which produced marked clinical toxicity (NTP, 2011). The pvalue for the trend test was not significant for this study due to the downturn in micronuclei induction at the highest dose. In a parallel study, 2,4-decadienal dissolved in corn oil as a carrier was administered to mice (5 males/dose) by 3 intraperitoneal injections at 24 hours intervals, at doses of 25, 50, 100 and 200 mg/kg bw. Cyclophosphamide (25 mg/kg bw) was given as the positive control. Mice from all groups were sampled 24 hours after the final dosing. Only 1000 PCEs were scored for each animal for MN instead of 2000 as recommended in OECD Guidelines 474 (OECD, 1997b) . A trend of increase in micronuclei frequency is evident in the range of doses 25 -200 mg/kg bw, but no statistically significant difference with respect to the control was observed at any dose level of 2,4-decadienal. It should be noted that the mean micronuclei frequency in control group (1.2 per 1000 cells) is twofold compared with the value at the lowest dose tested (NTP, 2011) .
In a second experiment of the above study, mice (5 males/dose) were administered a single intraperitoneal injection of 400 or 600 mg/kg bw of 2,4-decadienal dissolved in corn oil. Bone marrow and peripheral blood were sampled 48 hours post dosing. A statistically significant increase in micronucleated polychromatic erythrocytes was observed for the 600 mg/kg bw group (3.5 fold compared to control). Analysis of peripheral blood polychromatic erythrocytes in these same mice did not show a statistically significant increase in the frequency of micronucleated cells.
The evaluation of the peripheral blood sampled from male and female mice at the end of a 90-day gavage toxicity study at doses of 0, 50, 100, 200, 400, or 800 mg/kg, 5 days per week for 14 weeks, by the same laboratory, showed no increase in the frequency of micronucleated reticulocytes in treated groups compared with controls. No relevant treatment-related hematological effects were described with the exception of a minimal treatment-related, but not dose-related, decreases in hematocrit values, hemoglobin concentrations and erythrocyte counts occurred in the higher-dosed male and/or female mice. No data on clinical signs, bone marrow toxicity and blood analysis are available to demonstrate the systemic exposure (NTP, 2011).
Overall, the Panel noted that a statistically significant increase of micronucleated polychromatic erythrocytes was observed in both rats and mice up to 6-fold and 3.5-fold compared to control, respectively. Therefore, the Panel considered that 2,4-decadienal cannot be considered non-genotoxic in vivo after intraperitoneal injection.
Study validation and results are presented in Table 9 .
Literature data on hexa-2(trans),4(trans)-dienal [FL-no: 05.057] and 2,4-Decadienal [FL-no: 05.140]
For hexa-2(trans),4(trans)-dienal [FL-no: 05.057] no new experimental data have been submitted by Industry, but additional data from literature including a IARC monograph (IARC, 2012).
Hexa-2(trans),4(trans)-dienal [FL-no: 05.057] tested in V79 and in Caco-2 cells through a comet assay, induced a concentration-dependent induction of DNA damage, in association with a depletion of glutathione levels (Glaab et al., 2001) . The production of oxidative DNA damage (FPG-sensitive sites detected by comet assay) by 2,4-hexadienal was demonstrated to be the consequence of the glutathione depletion in V79 cells (Janzowski et al., 2003) . 2,4-hexadienal produced 1,N2-cyclicdeoxyguanosine and 7,8-cyclic-guanosine adducts in a cell-free system (Eder et al., 1993) . Crotonaldehyde-deoxyguanosine-2 adduct levels determined by a 32 P-postlabeling technique were increased in forestomach but not in liver of rats exposed to 2,4-hexadienal at a dose of 90 mg/kg bw by gavage for 90 days (NTP, 2003) . These results suggest that treatment with 2,4-hexadienal may increase cyclic adduct formation in rat forestomach DNA via a lipid peroxidation pathway (NTP, 2003) . Reactive oxygen species can cause DNA damage in forestomach in the form of 8hydroxydeoxy-guanosine. According to IARC (2012), the increase in chronic inflammation of the forestomach and the presence of forestomach ulcers observed in the high-dose group of male rodents in the 2-year study (NTP, 2003) does not support the hypothesis that the dose-related increases in forestomach neoplasms in male and female rodents is due only to 2,4-hexadienal cytotoxicity. IARC classified 2,4-hexadienal as possible carcinogen to humans and concluded that "mechanistic data provide additional support for the relevance of the animal carcinogenicity data to humans" and that "there is a moderate evidence that tumour induction occurs via a genotoxic mechanism".
A number of papers are also available in the scientific literature related to the mechanism of action of the genotoxic damage induced by 2,4-decadienal.
The reaction of 2,4-decadienal with 2-deoxyguanosine results in the production of a number of base derivatives. Six different stable DNA adducts (hydroxyl-etheno-dGua derivatives) were isolated by reverse-phase HPLC and fully characterised with spectroscopic measurements, following in vitro treatment of calf thymus DNA with 2,4-decadienal (Loureiro et al., 2000 and .
A number of studies report the induction of DNA damage in human cells in culture.
Treatment of human erythroleukemia cell line (HEL cells) with 2,4-decadienal leads to a marked variation of the cellular glutathione level (GSH) and induces DNA fragmentation, as revealed by the presence of low molecular weight DNA fragments upon electrophoresis (Nappez et al., 1996) .
It has been shown that 2,4-decadienal induces intracellular ROS, (determined by dichlorofluorescein assay) and causes significant oxidative damage of the 8-hydroxy-2'-deoxyguanosine in lung adenocarcinoma cell line A549 at concentrations from 50 to 200 µM (Wu and Yen, 2004) .
Significant induction of DNA strand breaks, detected by comet assay, was observed in vitro in human bronchiolar epithelial cells (BEAS-2B) after 4 hours of exposure to 1 µM of 2,4-decadienal. The extent of DNA fragmentation was significantly reduced by the co-treatment with antioxidants, such as NAC, SOD and catalase, indicating that an oxidative stress is involved in the process of DNA breakage.
A significant enhancement of the DNA damage induced by the treatment with 2,4-decadienal was observed through an in vitro challenge with Endo III/Fpg (a group of repair enzymes that specifically recognize and repair oxidised purines and pyrimidines) after 1 hour of treatment, and with NER (nucleotide excision repair) enzymes after 4 hours of treatment (Young et al., 2010) . These results reveal that 2,4-decadienal induces two different types of DNA damage: oxidised DNA bases and formation of bulky adducts. The results indicate that, in addition to early oxidative DNA damage, nonoxidative DNA damage, such as bulky adduct formation, was also induced by 2,4-decadienal (Young et al., 2010) .
Discussion of available data
In FGE.203, the Panel noted that 2,4-hexadienal [FL-no: 05.057] increased the incidence of neoplasms in the forestomach of male and female rats and mice in a 2-year carcinogenicity study. In addition, squamous cell carcinoma of the tongue has been observed in two mice of the high dose group (NTP, 2003) . The Panel noted that tongue cancer is generally rare in laboratory animals and that it could be relevant for humans.
On the basis of the evidence from the additional papers reporting the induction of DNA adducts in different systems in vitro and in vivo and of the IARC classification of 2,4-hexadienal as "possible carcinogen to humans" and considering the conclusion drawn by IARC that "mechanistic data provide additional support for the relevance of the animal carcinogenicity data to humans" and that "there is a moderate evidence that tumour induction occurs via a genotoxic mechanism" the Panel confirms the safety concern for 2,4-hexadienal.
2,4-Decadienal was tested for genotoxicity in a NTP study (NTP, 2011) . No increase in revertants was observed in any of the several strains of S. typhimurium tested with and without liver S9 activation enzymes. According to the authors of the NTP report, the in vivo micronucleus tests in rats and mice produced mixed results. The conclusion of the NTP study report is that 2,4-decadienal was not mutagenic in vitro or in vivo. The Panel, however, noted that statistically significant increases in the frequency of micronuclei in PCE were observed with 2,4-decadienal up to 6-fold in rats without a dose-response relationship and in mice at a single dose level (3.5-fold compared to controls), after intraperitoneal injection in the NTP study. The Panel also noted that the negative result of the micronucleus assay performed in the 90-day study by gavage, without any evidence of a systemic exposure, cannot overrule the effects observed in rats and mice after an acute exposure. Based on these considerations, the Panel did not agree with the authors of the NTP report and concluded that 2,4decadienal cannot be considered non-genotoxic in vivo in rats and mice after intraperitoneal injection.
On the basis of the overall evaluation of the genotoxicity data of 2,4-decadienal showing some indication for genotoxicity in vivo and considering the evidence from in vitro studies for the induction of different types of DNA damage (oxidised DNA bases and bulky adducts) a non-threshold mechanism of genotoxicity cannot be excluded for 2,4-decadienal.
CONCLUSION
The Panel considered that a non-threshold mechanism of action cannot be excluded for both representative substances based on the data available. The Panel concluded that the safety concern cannot be ruled out for the representative substances hexa-2(trans),4(trans)-dienal [FL-no: 05.057] and for 2,4-decadienal ]. Therefore, the substances of this FGE cannot be evaluated through the Procedure. The genotoxicity data available could not rule out the concern for genotoxicity.
SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 203REV1
1174
Hexa-2,4-dien-1-ol ND 0.4
Class I A3: Intake below threshold (d) Evaluated in FGE.203Rev1. The genotoxicity data available could not rule out the concern for genotoxicity.
1183
Nona-2,4-dien-1-ol ND 26
Class I A3: Intake below threshold
The genotoxicity data available could not rule out the concern for genotoxicity.
1175
Hexa-2(trans),4(trans)dienal 0.97 0.1 Class I A3: Intake below threshold (d) Evaluated in FGE.203Rev1. The genotoxicity data available could not rule out the concern for genotoxicity.
1198
Trideca-2(trans),4(cis),7(cis)trienal 0.18 0.009 Class I A3: Intake below threshold (d) Evaluated in FGE.203Rev1. The genotoxicity data available could not rule out the concern for genotoxicity.
1185
Nona-2,4-dienal 1.5 0.7 Class I A3: Intake below threshold
1179
Hepta-2,4-dienal 3.0 23 Class I A3: Intake below threshold (d) Evaluated in FGE.203Rev1. The genotoxicity data available could not rule out the concern for genotoxicity.
1173
Penta 
EFSA conclusion on the named compound
could not rule out the concern for genotoxicity.
1195
Undeca-2,4-dienal 3.2 0.4
1196
Dodeca-2,4-dienal 0.57 0.1 Class I A3: Intake below threshold (d) Evaluated in FGE.203Rev1. The genotoxicity data available could not rule out the concern for genotoxicity.
1181
Octa-2(trans),4(trans)dienal 0.55 0.007 Class I A3: Intake below threshold
1190
Deca-2(trans),4(trans)dienal 22 70
1784
Hepta-2,4-dien-1-ol 0.061 0.01 Class I B3: Intake below threshold, B4: Adequate NOAEL exists (d) Evaluated in FGE.203Rev1. The genotoxicity data available could not rule out the concern for genotoxicity.
1786
Deca-2,4,7-trienal 0.12 0.01 Class I B3: Intake below threshold, B4: Adequate NOAEL exists
1785
Nona-2,4,6-trienal 0.0012 ND Class I B3: Intake below threshold, B4: Adequate NOAEL exists (d) Evaluated in FGE.203Rev1. The genotoxicity data available could not rule out the concern for genotoxicity. EFSA conclusion on the named compound B4: Adequate NOAEL exists could not rule out the concern for genotoxicity.
2,4-Decadienal 27 No evaluation
Not evaluated by the JECFA.
Evaluated in FGE.203Rev1. The genotoxicity data available could not rule out the concern for genotoxicity.
2,4-Octadienal 0.65 No evaluation
05.194
tr-2, tr-4-Nonadienal 2.9 No evaluation Not evaluated by the JECFA.
05.196
tr-2, tr-4-Undecadienal
No evaluation
Evaluated in FGE.203Rev1. The genotoxicity data available could not rule out the concern for genotoxicity. (a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. (b): Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. (c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. (d): No safety concern based on intake calculated by the MSDI approach of the named compound. (e): Data must be available on the substance or closely related substances to perform a safety evaluation. ND: not determined. 
